###begin article-title 0
###xml 85 89 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice
###end article-title 0
###begin p 1
###xml 186 202 186 202 <email xmlns:xlink="http://www.w3.org/1999/xlink">majid@tulane.edu</email>
Address for reprint requests and other correspondence: D. S. A. Majid, Dept. of Physiology, SL-39, Tulane Univ. Health Sciences Center, 1430 Tulane Ave., New Orleans, LA 70112 ( e-mail: majid@tulane.edu)
###end p 1
###begin p 2
This document may be redistributed and reused, subject to .
###end p 2
###begin p 3
###xml 295 297 279 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 301 303 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 680 681 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 745 747 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 749 751 721 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 799 801 767 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 803 805 771 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 877 879 840 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 881 883 844 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1075 1077 1026 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1079 1081 1030 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1182 1183 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1343 1344 1282 1283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1344 1345 1283 1284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1372 1374 1310 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1378 1380 1316 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1382 1383 1320 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1451 1452 1389 1390 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1485 1487 1422 1424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1491 1493 1428 1430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1495 1496 1432 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1733 1734 1662 1663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1734 1735 1663 1664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 321 325 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1309 1313 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Tumor necrosis factor-alpha (TNF-alpha) has been implicated in the pathogenesis of hypertension and renal injury. However, the direct effects of TNF-alpha on renal hemodynamic and excretory function are not yet clearly defined. We examined the renal responses to infusion of TNF-alpha (0.33 ng.g-1.min-1) in anesthetized mice. Renal blood flow (RBF) and glomerular filtration rate (GFR) were determined by PAH and inulin clearance. The urine was collected from a cannula inserted into the bladder. Following the 60-min control clearance period, TNF-alpha infusion was initiated and 15 min were given for stabilization followed by another 60-min clearance period. TNF-alpha alone (n = 7) caused decreases in RBF (7.9 +/- 0.3 to 6.4 +/- 0.3 ml.min-1.g-1) and GFR (1.04 +/- 0.06 to 0.62 +/- 0.08 ml.min-1.g-1) as well as increases in absolute (0.8 +/- 0.3 to 1.4 +/- 0.3 mumol.min-1.g-1) and fractional excretion of sodium (0.5 +/- 0.2 to 1.5 +/- 0.4%) without affecting arterial pressure. TNF-alpha also increased 8-isoprostane excretion (8.10 +/- 1.09 to 11.13 +/- 1.34 pg.min-1.g-1). Pretreatment with TNF-alpha blocker etanercept (5 mg/kg sc; 24 and 3 h before TNF-alpha infusion; n = 6) abolished these responses. However, TNF-alpha induced an increase in RBF and caused attenuation of the GFR reduction in mice pretreated with superoxide (O2-) scavenger tempol (2 mug.g-1.min-1; n = 6). Pretreatment with nitric oxide (NO) synthase inhibitor nitro-l-arginine methyl ester (0.1 mug.g-1.min-1; n = 6) resulted in further enhancement in vasoconstriction while natriuresis remained unaffected in response to TNF-alpha. These data suggest that TNF-alpha induces renal vasoconstriction and hypofiltration via enhancing the activity of O2- and thus reducing the activity of NO. The natriuretic response to TNF-alpha is related to its direct effects on tubular sodium reabsorption.
###end p 3
###begin p 4
###xml 140 153 140 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 4
###begin p 5
###xml 0 27 0 23 <sc xmlns:xlink="http://www.w3.org/1999/xlink">tumor necrosis factor-&#945;</sc>
###xml 274 275 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 277 279 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 295 297 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 517 519 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 549 551 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 582 584 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 678 680 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 722 724 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 726 728 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 813 815 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 873 874 853 854 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 985 986 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 988 990 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 1193 1195 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 1279 1281 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1283 1285 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1539 1541 1507 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 672 676 <span type="species:ncbi:10116">rats</span>
###xml 716 720 <span type="species:ncbi:10116">rats</span>
###xml 807 811 <span type="species:ncbi:10116">rats</span>
tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine produced by leukocytes, monocytes, and macrophages. However, it can also be generated by endothelial cells and in the kidney by mesangial and tubular epithelial cells upon inflammation and tissue injury (3, 54). Dong et al. (12) showed that resident dendritic cells in the kidney are the predominant TNF-alpha-secreting cells in early renal ischemia-reperfusion injury. ANG II has also been reported to increase TNF-alpha production in monocytes (25), in renal epithelial cells (16), and in the mammalian heart (30). Increased production of TNF-alpha has been reported in ANG II-dependent hypertensive rats (17) as well as in Dahl salt-sensitive rats (13, 21) and is involved in the progression of renal injury in chronic ANG II-infused rats (14). Inhibition of angiotensin-converting enzyme (ACE) or AT1 receptors attenuates renal tubulointerstitial injury and reduces expression of cytokines and matrix proteins (7, 46). Moreover, ANG II-induced hypertension is considered a chronic inflammatory disorder characterized by growth of vascular smooth muscle cells, proliferation and infiltration of monocytes in the kidney (29), and increased production of proinflammatory cytokine TNF-alpha by T lymphocytes (23, 48). It has been demonstrated that T cells are activated to increase the production of TNF-alpha in ANG II-induced hypertension. Furthermore, blockade of TNF-alpha normalized blood pressure and vascular superoxide production in this model of hypertension (23).
###end p 5
###begin p 6
###xml 191 193 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 396 398 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 425 427 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 764 765 752 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 792 794 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 796 798 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 107 111 <span type="species:ncbi:10116">rats</span>
In addition, it has been reported that TNF-alpha mediates renal injury in Dahl salt-sensitive hypertensive rats via activation of NADPH oxidase and reduced nitric oxide (NO) bioavailability (50). In aortic endothelial cells, TNF-alpha has been reported to potentiate protein tyrosine nitration through activation of both NADPH oxidase and the endothelial isoform of nitric oxide synthase (eNOS) (52). Furthermore, Li et al. (37) demonstrated that TNF-alpha mediates the mechanical trauma-induced myocardial apoptosis via oxidative and nitrosative stress by increasing NADPH oxidase and NOS expression. Interestingly, hypertension induced by chronic administration of a subpressor dose of ANG II has been reported to be associated with activation of NADPH oxidase (8) and upregulation of NOS (28, 31).
###end p 6
###begin p 7
###xml 249 250 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 250 251 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 512 516 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Collectively, the aforementioned data suggest that TNF-alpha plays an important role in ANG II-dependent and other forms of hypertension and that it might produce its effects by regulating the activity of NADPH oxidase and NOS and thus superoxide (O2-) and NO production. However, the role of TNF-alpha in renal hemodynamic and excretory function is not yet clearly defined. Thus the present study was designed to examine the renal responses to acute intravenous administration of human recombinant TNF-alpha in mice.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Animal Preparation
###end title 9
###begin p 10
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 989 990 983 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1102 1103 1096 1097 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1109 1110 1103 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 194 198 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 790 794 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1572 1578 <span type="species:ncbi:9913">bovine</span>
All the experimental procedures described in this study were performed in accordance with the guidelines and practices established by the Tulane University Animal Care and Use Committee. C57BL6 mice (Jackson Laboratories, Bar Harbor, ME), weighing between 22 and 25 g, were housed in a temperature- and light-controlled room and allowed free access to a standard diet (Ralston-Purina, St. Louis, MO) and tap water. The animals were anesthetized with a combination of Inactin (thiobutabarbital sodium, 100 mg/kg ip, Sigma, St. Louis, MO) and ketamine (6 mg/kg ip, Vedco, St. Joseph, MO) to measure renal blood flow (RBF), glomerular filtration rate (GFR), and renal excretory function as described before (27). Supplemental doses of ketamine (6 mg/kg iv) were administrated as required. The mice were placed on a servo-controlled surgical table that maintained body temperature at 37degreesC, and a tracheostomy was performed. The animals were allowed to breathe air enriched with oxygen (O2) by placing the exterior end of the tracheal cannula inside a small plastic chamber into which humidified 95% O2-5% CO2 was continuously passed. The right carotid artery was cannulated with polyethylene tubing (PE-10) connected to a pressure transducer (AcqKnowledge data acquisition system, Biopac) for continuous recording of arterial pressure (MAP) and heart rate (HR). The right jugular vein was catheterized with a PE-10 tube for fluid infusion at a rate of 3 mul/min with the help of an infusion pump (CMA). During surgery, an isotonic saline solution containing 6% albumin (bovine serum, Calbiochem, La Jolla, CA) was infused. The bladder was catheterized with a PE-90 tube via a suprapubic incision for urine collection. After surgery, the infusion fluid was replaced with an isotonic saline solution containing 1% albumin, 7.5% inulin (Inutest, Laevosan, Linz/Donau, Austria), and 1.5% PAH (Merck Sharpe & Dohme, West Point, PA), which was also used as vehicle for TNF-alpha infusion solution.
###end p 10
###begin title 11
Experimental Protocol
###end title 11
###begin p 12
###xml 42 46 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Two sets of experiments were conducted in mice: responses to a single-dose infusion of TNF-alpha and the dose-response relationship of TNF-alpha.
###end p 12
###begin p 13
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 251 252 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 254 256 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 422 423 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 730 731 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 787 788 763 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 803 804 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 821 822 797 798 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 846 847 822 823 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 854 855 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1025 1027 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1228 1230 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1367 1368 1323 1324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1368 1369 1324 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1474 1475 1426 1427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1475 1476 1427 1428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1540 1542 1491 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1546 1548 1497 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1639 1640 1586 1587 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1728 1729 1671 1672 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1767 1769 1709 1711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1773 1775 1715 1717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1823 1824 1761 1762 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1959 1960 1893 1894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 1084 1088 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1167 1171 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1233 1237 <span type="species:ncbi:10090|species:ncbi:10095">Mice</span>
###xml 1442 1446 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1604 1608 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
In the first set of experiments, responses to a single-dose (0.33 ng.g-1.min-1 iv) infusion of human recombinant TNF-alpha (Invitrogen-Biosource) were assessed. This dose of TNF-alpha was selected from the findings of previous studies with TNF-alpha (5, 41). We considered this dose of TNF-alpha as physiologically relevant because it was lower than the dose that was used to induce cytokine-mediated cardiac dysfunction (5). This dose did not alter systemic arterial pressure significantly and thus allowed us a reasonable assessment of the renal responses to TNF-alpha without any confounding arterial pressure-induced effects in the kidney. Responses to this single-dose infusion of TNF-alpha were assessed in control animals (n = 7) as well as in animals pretreated with etanercept (n = 6), tempol (n = 6), and nitro-l-arginine methyl ester (l-NAME; n = 6). Etanercept (Immunex), a TNF-alpha blocker, is a fusion protein which binds with circulating TNF-alpha and prevents it from acting on cellular TNF-alpha receptors (47). Etanercept was administered (5 mg/kg sc) in conscious mice 1 day before the experiment. A second dose was also given to the anesthetized mice 3 h before TNF-alpha infusion on the day of experiment (36). Mice pretreated with etanercept were considered to determine the specificity of the responses to TNF-alpha. To determine the role of O2- production in the responses to TNF-alpha, experiments were conducted in mice pretreated with tempol, a O2- scavenging agent. Tempol (Sigma) was given at a rate of 2 mug.g-1.min-1 starting 2 h before TNF-alpha infusion. Experiments in mice pretreated with NOS inhibitor l-NAME (Sigma) were conducted to determine the role of NO in the responses to TNF-alpha. l-NAME was given at a rate of 0.1 mug.g-1.min-1 starting 2 h before TNF-alpha infusion. Tempol/l-NAME infusions were continued until the end of experiments along with TNF-alpha infusion. A separate set of time control experiments (n = 7) was also conducted with a similar protocol with vehicle (saline) infusion without TNF-alpha.
###end p 13
###begin p 14
###xml 502 504 493 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 508 510 499 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 94 98 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The basic protocol with infusion of TNF-alpha in all the experiments in treated and untreated mice described earlier was as follows. After a 60-min equilibration period following completion of surgical procedures, two consecutive 30-min control urine collections (basal period) were made. An arterial blood sample (100 mul) was then taken for measurements of basal hematocrit and plasma PAH, inulin, and sodium/potassium concentrations. Then, an infusion of TNF-alpha was started at a rate of 0.33 ng.g-1.min-1 and continued until the end of the experiment. Fifteen minutes after the initiation of TNF-alpha infusion (stabilization period), another two 30-min urine clearance collections were made (treatment period). After the final collection period, another arterial blood sample (100 mul) was taken for measurements of hematocrit, plasma PAH, inulin, and sodium/potassium concentrations. At the end of the experiment, the animals were killed with a high dose of ketamine (60 mg/kg iv) and the kidneys were removed and weighed.
###end p 14
###begin p 15
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 179 181 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 185 187 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 247 249 243 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 253 255 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 724 726 715 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 730 732 721 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 881 883 868 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 887 889 874 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1053 1055 1036 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1059 1061 1042 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 45 49 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
A second set of experiments was conducted in mice (n = 5) to determine the dose-response relationship of TNF-alpha which was infused at incremental doses of 0.1, 0.3, and 0.5 ng.g-1.min-1. These doses were considered to include the dose (0.33 ng.g-1.min-1) in earlier experiments at the mid-range level. The protocol in these experiments was as follows. After a 60-min equilibration period following completion of surgical procedures, two consecutive 30-min control urine collections (basal period) were made. An arterial blood sample (100 mul) was then taken for measurements of basal hematocrit and plasma PAH, inulin, and sodium/potassium concentrations. Then, an infusion of TNF-alpha was initiated at a rate of 0.1 ng.g-1.min-1 and after a 15-min of stabilization period, a 30-min urine collection was made. Another infusion of TNF-alpha was then started at a rate of 0.3 ng.g-1.min-1 and after a 15-min stabilization period, another 30-min urine collection was made. Subsequently, third infusion of TNF-alpha was then started at a rate of 0.5 ng.g-1.min-1 and after a 15-min stabilization period, a final 30-min urine clearance collection was done. At the end of this urine collection, another arterial blood sample (100 mul) was taken for measurements of hematocrit, plasma PAH, inulin, and sodium/potassium concentrations. The animals were then killed and kidneys were taken out and weighed.
###end p 15
###begin title 16
TNF-alpha RNA Isolation and Real-Time RT-PCR in Renal Tissues
###end title 16
###begin p 17
###xml 729 731 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
Total RNA was extracted from the preserved kidney by using TRIzol reagent provided by the manufacturer (Invitrogen) and was reverse transcribed by using oligo (dT) and reverse transcriptase. Expression levels of TNF-alpha mRNA were determined by using specific primers. GAPDH was used as a housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384-well PCR plates with the use of Bio-Rad PCR Master Mix (iTaq SYBR Green Supermix with ROX) and the ABI Prism 7900 sequence-detection system (Applied Biosystems). The primer sequences for real-time PCR for GAPDH were AGACAGCCGCATCTTCTTGT (forward) and CTTGCCGTGGGTAGAGTCAT (reverse) and for TNF-alpha were GTCGTAGCAAACCACCAAGC (forward) and TGTGGGTGAGGAGCACATAG (reverse) (41).
###end p 17
###begin title 18
Calculations and Statistical Analysis
###end title 18
###begin p 19
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 218 221 218 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 743 745 743 745 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 786 788 786 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 1493 1494 1483 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1710 1711 1700 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Urine volume (V) was measured gravimetrically. Blood and urine samples collected during systemic experiments were analyzed for inulin, PAH, and sodium/potassium concentrations as reported earlier (27). 8-Isoprostane (UIsoV) concentration in the urine was measured by enzyme immunoassay (Cayman Chemical) (33). Inulin and PAH concentrations were determined by spectrophotometry, and sodium/potassium concentrations were determined by flame photometry. The value for inulin clearance is considered as GFR, and the value for PAH clearance is considered as renal plasma flow. RBF is calculated from renal plasma flow and hematocrit values. The concentrations of sodium in urine and blood were used to calculate the urinary sodium excretion rate (UNaV) and fractional excretion of sodium (FENa), respectively. Renal vascular resistance (RVR) is calculated by dividing the value of mean systemic arterial pressure with the value of RBF. The mean values obtained during the first two control collection periods were considered as "basal values," while the mean of the values collected during the two TNF-alpha infusion periods was taken as the "treatment value." The differences in the values between the basal and the treatment periods are considered as the responses to TNF-alpha treatment. All values were normalized per gram of kidney weight. Results are expressed as means +/- SE. Differences between basal and treatment values in the same set of experiments were analyzed by a paired Student's t-test. Comparison of the data among the different set of experiments was made by one-way ANOVA, followed by the Student-Newman-Keuls post hoc test for multiple comparisons. Differences were considered significant at P < 0.05.
###end p 19
###begin title 20
RESULTS
###end title 20
###begin title 21
First Set of Experiments
###end title 21
###begin title 22
Responses to single-dose infusion of TNF-alpha on MAP and HR.
###end title 22
###begin p 23
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 335 336 315 316 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 952 953 900 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1082 1083 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1097 1098 1037 1038 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1154 1155 1090 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1218 1219 1154 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1225 1226 1161 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1286 1287 1218 1219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1515 1516 1431 1432 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1583 1584 1495 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1825 1826 1721 1722 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
At the dose of 0.33 ng.g-1.min-1, TNF-alpha infusion per se was found to have no significant effect on MAP. The responses to TNF-alpha in different group of experiments were as follows: control group: 100 +/- 3 to 99 +/- 4 mmHg; etanercept treated-group: 96 +/- 2 to 95 +/- 2 mmHg; tempol-treated group: 80 +/- 4 to 82 +/- 3 mmHg; and l-NAME-treated group: 131 +/- 3 to 129 +/- 5 mmHg. A small decrease in MAP was observed in all the animals due to the first blood collection, which was the same (approximately7 mmHg) in all the experimental groups. Once the MAP recordings reached a stabilized level after the first blood sample collection (usually taking 3-5 min), TNF-alpha infusion was initiated. There were significant increases in HR during TNF-alpha infusion, which was absent only in etanercept-treated animals. The HR responses to TNF-alpha in different groups of experiments were as follows: control group: 466 +/- 6 to 541 +/- 11 beats/min (P < 0.05); etanercept-treated group: 456 +/- 8 to 481 +/- 11 beats/min; tempol-treated group: 431 +/- 29 to 484 +/- 16 beats/min (P < 0.05); and l-NAME-treated group: 461 +/- 9 to 497 +/- 13 beats/min (P < 0.05). No significant differences were observed in plasma Na+ and K+ levels after TNF-alpha infusion in any group. The plasma Na+ levels after TNF-alpha infusion are as follows: control group: 150.4 +/- 0.8 to 152.4 +/- 1.3 meq/l; etanercept-treated group: 159.6 +/- 1.8 to 161.9 +/- 1.1 meq/l; tempol-treated group: 155.5 +/- 1.2 to 153 +/- 1.6 meq/l; and l-NAME-treated group: 157 +/- 3.1 to 154 +/- 1.9 meq/l. The plasma K+ levels after TNF-alpha infusion among different groups are as follows: control group: 4.3 +/- 0.1 to 4.5 +/- 0.3 meq/l; etanercept-treated group: 4.1 +/- 0.2 to 4.2 +/- 0.3 meq/l; tempol-treated group: 4.2 +/- 0.2 to 4.2 +/- 0.2 meq/l; and l-NAME-treated group: 4.6 +/- 0.3 to 4.7 +/- 0.3 meq/l.
###end p 23
###begin title 24
Responses to single-dose infusion of TNF-alpha on renal hemodynamics.
###end title 24
###begin p 25
###xml 93 100 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 143 149 139 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 159 160 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 151 160 147 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Figure 1<italic>A</italic></xref>
###xml 273 274 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 440 441 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 491 492 471 472 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 580 581 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 661 662 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 719 720 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 713 720 681 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 926 927 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 977 978 931 932 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1062 1063 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1149 1150 1093 1094 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1285 1286 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1277 1286 1217 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Figure 1<italic>C</italic></xref>
###xml 1408 1409 1338 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1645 1646 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1770 1771 1686 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1858 1859 1766 1767 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1926 1927 1832 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 356 360 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 782 786 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 992 996 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1381 1385 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1547 1551 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The absolute changes in RBF, RVR, and GFR in response to TNF-alpha infusion are given in the Table 1, and percent responses are illustrated in Fig. 1. Figure 1A illustrates the percent response of RVR to TNF-alpha treatment. TNF-alpha alone increases RVR by 20.4 +/- 5.4% (P < 0.05) from the baseline value, which was not observed in etanercept-pretreated mice. In the animals treated with tempol, TNF-alpha decreased RVR by 25.9 +/- 1.5% (P < 0.01) from the baseline value. In contrast, in l-NAME-treated animals, TNF-alpha infusion resulted in increases in RVR (36.1 +/- 10.4%; P < 0.05) from basal values. TNF-alpha infusion alone resulted in 18.9 +/- 4.8% (P < 0.05) decreases in RBF from the baseline value (Fig. 1B). This effect of TNF-alpha on RBF was found to be blocked in mice pretreated with the TNF-alpha blocker etanercept. However, in the tempol-treated animals, TNF-alpha markedly increased RBF (24.8 +/- 4.8%; P < 0.05) from the baseline value. In contrast, in l-NAME-treated mice, TNF-alpha infusion resulted in decreases in RBF (31.5 +/- 8.6%; P < 0.05 vs. baseline). The magnitude of this TNF-alpha-induced decrease in RBF during l-NAME treatment appears to be greater than that during TNF-alpha infusion alone, although found statistically not significant. Figure 1C illustrates the GFR responses to acute TNF-alpha infusion. TNF-alpha infusion in anesthetized mice caused 40.7 +/- 7.3% (P < 0.01) decreases in GFR from the baseline value. The reduction in GFR by TNF-alpha was found to be blocked in the etanercept-pretreated mice. In addition, in the animals treated with tempol, TNF-alpha caused decreases (21.2 +/- 5.4%; P < 0.05) in GFR from basal values. The magnitude of TNF-alpha-induced decreases in GFR during tempol treatment was smaller (P < 0.05) than that during TNF-alpha infusion alone. Furthermore, TNF-alpha infusion in l-NAME-treated animals also caused decreases in GFR (29.6 +/- 8.7%; P < 0.05) from the baseline value.
###end p 25
###begin title 26
Responses to single-dose infusion of TNF-alpha on renal excretory function.
###end title 26
###begin p 27
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Figure 2</xref>
###xml 162 163 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 178 179 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 172 179 162 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 183 185 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 205 206 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 221 222 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 215 222 203 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 231 233 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 252 253 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 268 269 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 262 269 248 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 438 439 416 417 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 510 511 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 539 540 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 727 729 689 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 748 749 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 764 766 724 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 786 787 744 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 881 883 835 837 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 891 893 845 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 931 932 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 998 999 948 949 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1061 1063 1007 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 1083 1084 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1099 1101 1043 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 1120 1121 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1206 1208 1144 1146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 1219 1220 1157 1158 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1404 1406 1337 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1408 1410 1341 1343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1412 1413 1345 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1423 1430 1356 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 111 115 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 405 409 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Figure 2 illustrate the effects of TNF-alpha infusion on renal excretory function. TNF-alpha infusion alone in mice caused marked increases in V (69.5 +/- 21.1%; P < 0.05; Fig. 2A), UNaV (106.1 +/- 17.8%; P < 0.01; Fig. 2B), and FENa (215.3 +/- 51.9%; P < 0.05; Fig. 2C) from their respective baseline values. These effects of TNF-alpha were not observed when TNF-alpha was given to etanercept-pretreated mice. Moreover, during tempol or l-NAME treatment also, TNF-alpha caused increases in V (96.1 +/- 15.0%; P < 0.01 and 94.7 +/- 35.4%; P < 0.05) from their respective baseline values, which were similar to those during TNF-alpha treatment alone. However, during tempol treatment, TNF-alpha resulted in marked increases in UNaV (196.9 +/- 6.2%; P < 0.01) and FENa (465.5 +/- 128.8%; P < 0.05) from their respective baseline values. The degree of TNF-alpha-induced increases in UNaV and FENa during tempol treatment was greater (P < 0.05) than that during TNF-alpha infusion alone. Similarly, in l-NAME-treated animals, TNF-alpha caused similar increases in UNaV (117.6 +/- 14.7%; P < 0.01) and FENa (287.7 +/- 52.2%; P < 0.05) from their respective baseline values, as by TNF-alpha alone. The baseline UNaV value in l-NAME-treated animals was higher than that in vehicle-treated animals; however, this difference was only borderline significant statistically (1.31 +/- 0.30 vs. 0.69 +/- 0.17 mumol.min-1.g-1; P = 0.062; Table 1).
###end p 27
###begin p 28
###xml 87 94 83 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 160 163 150 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 166 167 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 369 372 347 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 403 404 381 382 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 459 462 433 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 481 482 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 580 583 548 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 592 593 560 561 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 118 122 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 295 299 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Urinary 8-isoprostane excretion rate responses to TNF-alpha infusion are summarized in Table 1. TNF-alpha infusion in mice caused 38.01 +/- 2.86% increases in UIsoV (P < 0.01) from the baseline value. This response to TNF-alpha was not observed when TNF-alpha was given to etanercept-pretreated mice. Similarly, during tempol treatment, TNF-alpha-induced increases in UIsoV were absent. However, during l-NAME treatment, TNF-alpha caused marked increases in UIsoV (52.62 +/- 6.71; P < 0.01) from the baseline value. Although the magnitude of these TNF-alpha-induced increases in UIsoV during l-NAME treatment appears to be higher than those during TNF-alpha infusion alone, it was not statistically significant.
###end p 28
###begin p 29
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 274 276 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 278 280 266 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 329 331 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 375 377 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 379 381 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 420 422 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 424 426 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 429 431 404 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 474 476 444 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 478 480 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 484 486 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 522 523 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">K</sub>
###xml 566 568 527 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 570 572 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 575 578 536 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 617 619 574 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 621 623 578 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 638 639 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 645 646 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
In time control (vehicle treated) experiments (n = 7), no significant difference was observed between the basal and treatment period values, which were as follows: MAP, 89 +/- 4 to 91 +/- 4 mmHg; HR, 468 +/- 11 to 499 +/- 32 beats/min; RBF, 8.0 +/- 0.9 to 7.7 +/- 0.6 ml.min-1.g-1; RVR, 13.8 +/- 1.3 to 13.6 +/- 1.3 mmHg.ml.min.g-1; GFR, 1.00 +/- 0.04 to 1.07 +/- 0.06 ml.min-1.g-1; V, 8.4 +/- 1.7 to 7.8 +/- 1.6 mul.min-1.g-1; UNaV, 0.69 +/- 0.17 to 0.65 +/- 0.15 mumol.min-1.g-1; FENa, 0.53 +/- 0.15 to 0.52 +/- 0.17%; UKV, 1.55 +/- 0.25 to 1.59 +/- 0.06 mumol.min-1.g-1; UIsoV, 6.89 +/- 1.04 to 6.96 +/- 0.7 pg.min-1.g-1; and plasma Na+ and K+ concentration, 155.9 +/- 1.1 to 155.2 +/- 1.2 and 4.3 +/- 0.2 to 4.4 +/- 0.5 meq/l, respectively.
###end p 29
###begin title 30
Second Set of Experiments
###end title 30
###begin title 31
Responses to incremental doses of TNF-alpha on MAP, HR, renal hemodynamics and excretory function.
###end title 31
###begin p 32
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 77 85 73 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Figure 3</xref>
###xml 158 160 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 164 166 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 243 245 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 291 292 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 339 340 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 388 390 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 394 396 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 462 463 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 494 495 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 556 557 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 568 570 546 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 586 587 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 603 605 579 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 620 621 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 715 717 687 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 721 723 693 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 788 789 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 822 823 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 877 878 839 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 889 891 851 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 907 908 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 924 926 884 886 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 942 943 900 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1000 1001 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1058 1059 1014 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1065 1066 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1286 1288 1230 1232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1292 1294 1236 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1357 1359 1301 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1363 1365 1307 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
Table 2 summarizes the absolute responses to incremental doses of TNF-alpha. Figure 3 also illustrates some of these responses in percent changes. At 0.1 ng.g-1.min-1 infusion rate, TNF-alpha did not cause any significant change in MAP, RBF, UNaV, and V except an increase in HR (13 +/- 3%; P < 0.01) and a decrease in GFR (21.5 +/- 2.9%; P < 0.05) compared with basal values. At 0.3 ng.g-1.min-1, TNF-alpha resulted in a significant fall in RBF (11.1 +/- 1.5%; P < 0.05) and GFR (29.7 +/- 7%; P < 0.01) as well as significant increases in V (103 +/- 25%; P < 0.05), UNaV (142 +/- 31%; P < 0.05), and FENa (284 +/- 37%; P < 0.05) without altering MAP (2 +/- 1%) compared with baseline values. Similarly, at 0.5 ng.g-1.min-1 TNF-alpha also caused a significant fall in RBF (22.7 +/- 5.7%; P < 0.01) and GFR (41.3 +/- 8.9%; P < 0.01) and significant increases in V (120 +/- 43%; P < 0.05), UNaV (204 +/- 89%; P < 0.05), and FENa (518 +/- 105%; P < 0.01) along with a significant fall in MAP (9 +/- 2%; P < 0.01) compared with the baseline values. The plasma Na+ and K+ concentration measured before and after TNF-alpha infusions were not different and are as follows: 152.4 +/- 2.3 to 153.4 +/- 2.5 and 4.8 +/- 0.5 to 4.9 +/- 0.3 meq/l, respectively. The responses at the dose of 0.3 ng.g-1.min-1 were comparable with the responses to a single-dose (0.33 ng.g-1.min-1) infusion in the first set of experiments.
###end p 32
###begin title 33
###xml 74 76 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 80 82 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
Renal mRNA expression of TNF-alpha in response to a single-dose (0.33 ng.g-1.min-1) infusion of TNF-alpha.
###end title 33
###begin p 34
###xml 27 33 27 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 75 76 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 298 299 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 545 546 515 516 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 598 599 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 311 315 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Results are illustrated in Fig. 4. TNF-alpha infusion induced an increase (P < 0.05) in the mRNA levels of TNF-alpha (101 +/- 20-fold) in the kidney compared with control vehicle-treated animals. This increase in TNF-alpha expression in response to TNF-alpha infusion was significantly attenuated (P < 0.05) in mice pretreated with TNF-alpha blocker etanercept compared with the vehicle-treated animals. However, a significant increase in TNF-alpha expression was observed in response to TNF-alpha infusion in the animals treated with tempol or l-NAME (69 +/- 15- and 57 +/- 18-fold, respectively; P < 0.05) compared with vehicle-treated animals.
###end p 34
###begin title 35
DISCUSSION
###end title 35
###begin p 36
###xml 1007 1008 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1010 1012 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1014 1016 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1783 1785 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1787 1789 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
###xml 2076 2077 2020 2021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 2134 2135 2078 2079 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2249 2251 2193 2195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 2883 2885 2815 2817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 2887 2889 2819 2821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 3104 3106 3028 3030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 3456 3457 3376 3377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3463 3464 3383 3384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 106 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 292 296 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 2951 2955 <span type="species:ncbi:10116">rats</span>
###xml 3353 3357 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The present study demonstrated that acute administration of the proinflammatory cytokine TNF-alpha in mice resulted in decreases in RBF and in GFR but caused increases in urine flow and sodium excretion without altering arterial pressure. These renal responses to TNF-alpha were abolished in mice pretreated with the TNF-alpha blocker etanercept, confirming the specificity of these direct effects of TNF-alpha in the kidney. To our knowledge, this is the first study in which the direct effects of this cytokine on renal hemodynamics and excretory function were assessed. As TNF-alpha is released in the plasma during inflammatory conditions, it can exert its effects in different organ systems, including the kidney. The estimated renal plasma concentration of TNF-alpha achieved during the infusion period in the present study was approximately30 pmol, which was within the range of plasma concentrations of this cytokine reached during inflammatory conditions, as reported in many experimental studies (4, 23, 40). Thus the results obtained in the present study provide useful information regarding a possible physiological and pathophysiological role of this cytokine in the regulation of renal hemodynamics and excretory functions, particularly in the conditions that are associated with inflammatory responses. It should be noted here that the effect of exogenous TNF-alpha might be different in anesthetized and conscious animals. Indeed, various anesthetics have been shown to reduce the release of proinflammatory cytokines, including TNF-alpha, and reduce the lethality of lipopolysaccharide, which may result from the decrease in the activities of nuclear factor-kappaB and activator protein 1 and the reduction of the expression of p38 mitogen-activated protein kinase (19, 53). Thus it may be possible that exogenous administration of TNF-alpha can cause accentuated renal responses in conscious animals than those in anesthetized animals, and the present results may be interpreted accordingly. It could be argued that a centrally mediated action of TNF-alpha (1) can induce soluble mediators especially prostaglandin E2 within the cells of the blood-brain barrier that readily penetrate into the brain to initiate neural mechanisms (55) to alter sympathetic nerve activity. However, in the present study we found no change in blood pressure by TNF-alpha infusion, suggesting that the dose used in this study did not alter the sympathetic activity to a degree that could influence significantly renal hemodynamics and renal function. As TNF-alpha was observed to induce dose-dependent increases in HR along with no change (in low dose) or a decrease (in high dose) in arterial pressure, it can reasonably be assumed that this cytokine also decreased stroke volume. Previous studies also demonstrated an increase in HR in response to acute administration of TNF-alpha (20, 43). Although chronic administration of TNF-alpha for 5 days in rats did not affect HR or blood pressure, it caused a decrease in fractional shortening, indicating a systolic dysfunction in TNF-alpha-treated animals (41). In the present study, although HR increases, the presumed decreases in stroke volume/cardiac output may also indicate such systolic dysfunction in response to acute infusion of TNF-alpha. Although the plasma volume in these acute, anesthetized mice preparations was not measured in the present study, there were no significant changes in plasma Na+ and K+ concentrations following TNF-alpha infusion.
###end p 36
###begin p 37
###xml 29 30 29 30 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 260 261 256 257 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 517 518 501 502 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 943 944 907 908 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1050 1051 1010 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1051 1052 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1443 1445 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1447 1449 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1451 1453 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 1584 1586 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1649 1651 1597 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 2483 2485 2397 2399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 2534 2536 2448 2450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 2785 2790 2687 2692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 2909 2911 2803 2805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 3602 3603 3476 3477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 3603 3604 3477 3478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 286 290 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 544 548 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 891 895 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 961 965 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1704 1707 <span type="species:ncbi:10116">rat</span>
It could also be argued that l-NAME or tempol treatment might alter the effective plasma concentration of TNF-alpha in the kidney. This possibility seems unlikely as it was observed in the present study that basal levels of RBF were not much different between l-NAME- or tempol-treated mice, indicating that the kidneys in both conditions received more or less the same amount of TNF-alpha from its infusion. Moreover, TNF-alpha administration also induces similar levels of renal tissue TNF-alpha mRNA expression in l-NAME- and tempol-treated mice, indicating that the effective concentrations of TNF-alpha in the kidney in those two conditions might not be much different. We observed that TNF-alpha markedly increases the mRNA levels of TNF-alpha in the kidney. Moreover, the TNF-alpha-induced increase in TNF-alpha mRNA levels was found significantly attenuated in etanercept-pretreated mice; however, it remained unaffected in tempol- or l-NAME-pretreated mice, suggesting that TNF-alpha can induce its own mRNA message independently of NO and O2-, at least in the present experimental setting. This increase in the renal TNF-alpha mRNA expression due to exogenous TNF-alpha in this short period is interesting but consistent with many previous studies which demonstrated the significant increases in TNF-alpha mRNA expression in a time period as short as 30 min in response to different stimuli like ANG II or coronary artery occlusion (18, 30, 49). Moreover, it is a well-known property of the proinflammatory cytokines to amplify their own secretion in a feed-forward manner (11). By a well-organized and comprehensive study, Taishi et al. (49) very recently reported that TNF-alpha treatment in rat hypothalamic culture significantly increased IL-1beta (56-fold), TNF-alpha (43-fold), and IL-6 (5-fold) mRNA levels at 30 min. The same treatment with TNF-alpha of cortical culture increased mRNA levels of these genes further [IL-1beta (>30-fold), TNF-alpha (>50-fold), and IL-6 (30-fold)] at 30 min. These data suggest that TNF-alpha can increase its own as well as other cytokine expression over a time period as short as 30 min. As the present study was designed to determine the effect of circulating TNF-alpha on renal hemodynamic and function, we limit our assessment of the tissue mRNA levels only in the kidney; however, it should be noted here that such changes in tissue TNF-alpha mRNA level were also observed in the hypothalamus during coronary artery occlusion (18) or in myocardium during ANG II administration (30). The finding that etanercept did not completely block the tissue TNF-alpha mRNA induction by circulating TNF-alpha could be due to the fact that etanercept is a recombinant fusion protein which is a soluble TNF-alpha receptor. It does not bind to trans-membrane TNF-alpha as effectively as would be done by anti-TNF-alpha antibodies such as infliximab, adalimumab, etc. (47), indicating its reduced efficacy in intracellular targets, which could be the reason for this incomplete blockade of tissue TNF-alpha mRNA induction. The dose of etanercept used in the present study, although effective in preventing TNF-alpha-induced changes in renal hemodynamics and excretory function, may not be sufficient enough to prevent tissue TNF-alpha mRNA induction effectively. It should be noted here that the assessment of mRNA activity could not necessarily reflect protein activity; thus the mRNA data in this may be interpreted accordingly. However, it appears that exogenous TNF-alpha can stimulate the renal mRNA expression of TNF-alpha equally in the condition NOS or O2- inhibition.
###end p 37
###begin p 38
###xml 125 126 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 126 127 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 331 332 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 332 333 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 478 481 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 507 508 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 508 509 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 662 664 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 666 668 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 709 710 697 698 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 710 711 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 843 844 827 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 844 845 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 872 874 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 876 878 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 1110 1111 1090 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1111 1112 1091 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1185 1186 1165 1166 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1235 1236 1215 1216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1236 1237 1216 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1248 1250 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1252 1254 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1300 1301 1276 1277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1301 1302 1277 1278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1448 1451 1420 1423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 1460 1461 1432 1433 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1565 1566 1529 1530 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1709 1710 1673 1674 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1710 1711 1674 1675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1809 1810 1769 1770 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1810 1811 1770 1771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1917 1918 1877 1878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 2043 2044 1999 2000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2044 2045 2000 2001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 92 96 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 569 573 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 638 642 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 981 985 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1580 1584 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1609 1613 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The vasoconstrictor effect of TNF-alpha was not seen when this cytokine was administered in mice pretreated with tempol (an O2- scavenger). It was observed that TNF-alpha infusion in tempol-treated animals resulted rather in an increase in RBF and also an attenuation of reductions in GFR. These findings suggest that an enhanced O2- activity plays a role in mediating renal vasoconstrictor and hypofiltration responses to this cytokine. Indeed, there was an increased rate of UIsoV (a marker for enhanced O2- activity) in response to TNF-alpha administration in these mice that was ameliorated in etanercept as well as in tempol-treated mice. Previous studies (10, 39) also demonstrated that an increase in O2- activity during inhibition of superoxide dismutase enzyme exerted a renal vasoconstrictor response. TNF-alpha was shown to induce O2- as well as NO production (37, 52). Thus it is conceivable that the renal vasodilatory response to TNF-alpha observed in tempol-treated mice resulted from an enhancement of NO bioavailability due to an increase in the production of NO as well as to a reduction in O2- level, as the latter was scavenged by tempol. It has been reported that l-NAME administration resulted in an increase in O2- activity (32, 38). Thus the TNF-alpha-induced enhancement of O2- activity would be even greater in the condition of NOS inhibition than that in an intact condition. Indeed, TNF-alpha induced more increases in UIsoV during l-NAME treatment than TNF-alpha alone in the present study. The greater reduction in RBF by TNF-alpha in l-NAME-treated mice compared with untreated mice indicates that a concomitant increase in NO production helps to offset the action of enhanced O2- activity induced by TNF-alpha. It has also been suggested that in vascular smooth muscle cells, O2- could exert its direct vasoconstrictor action, possibly by enhancing intracellular calcium accumulation (9). Collectively, these results indicate that the effects of TNF-alpha on RBF and GFR are mediated by both an enhancement in O2- activity as well as a reduction in NO activity.
###end p 38
###begin p 39
###xml 210 211 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 268 271 268 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 336 337 336 337 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 381 384 381 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 421 422 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 422 423 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 547 548 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 548 549 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 640 643 636 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
###xml 673 674 669 670 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 744 745 740 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 745 746 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
8-Isoprostane is generally believed to be formed endogenously due to oxidation of membrane phospholipids by a potent oxidant, peroxynitrite, that is produced during an in vivo chemical reaction between NO and O2- (26, 45). However, it has also been demonstrated that UIsoV increased when endogenous NO production was inhibited by nitro-l-arginine administration. This increase in UIsoV was ameliorated completely by the O2- scavenger tempol, indicating that such increased formation of 8-isoprostane results from direct peroxidation of lipids by O2- (38, 44). In the present study, we also demonstrated that TNF-alpha-induced increases in UIsoV were more pronounced in the l-NAME-pretreated (NOS-inhibited) animals, supporting the notion that O2- can directly interact with lipids to produce 8- isoprostane.
###end p 39
###begin p 40
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 127 129 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 131 133 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 135 137 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 139 141 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 143 145 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 273 274 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 274 275 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 342 344 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 469 470 457 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 470 471 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 533 535 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 624 628 612 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 908 912 884 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 923 925 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 927 929 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1158 1160 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 698 702 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 744 748 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 783 787 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 806 811 <span type="species:ncbi:9606">human</span>
###xml 1122 1126 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The involvement of both O2- and NO production in the actions of TNF-alpha has been demonstrated in many experimental settings (22, 28, 36, 37, 50). In aortic endothelial cells, TNF-alpha has been reported to potentiate the protein tyrosine nitration and the production of O2- and NO through activation of NADPH oxidase and NOS, respectively (52). In cardiomyocytes, TNF-alpha has been reported to mediate nonlethal trauma-induced apoptosis by overproduction of NO and O2- via increased expression of inducible NOS and NADPH oxidase (37). Moreover, recently it has also been shown that ANG II increases the expression of gp91phox (a subunit of NADPH oxidase) and eNOS in the myocardium of wild-type mice, which were absent in TNF-alpha knockout mice. However, when TNF-alpha knockout mice were treated with human recombinant TNF-alpha, ANG II caused increases in blood pressure as well as upregulation of gp91phox and eNOS (22, 48). Preliminary data from our laboratory also demonstrated that ANG II-induced increases in urinary nitrate/nitrite and isoprostane excretion rate were significantly lower in TNF-alpha knockout mice compared with control animals (34).
###end p 40
###begin p 41
###xml 81 82 77 78 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 455 457 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 459 461 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 616 618 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 895 897 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
It was noted that TNF-alpha induced reduction in GFR was partially attenuated in l-NAME-treated animals but the reduction in RBF responses to TNF-alpha was further enhanced in these animals. These findings indicate that in the condition of NOS inhibition, TNF-alpha induced a similar influence on both preglomerular and postglomerular resistance segments that helped to maintain GFR although there was a marked decrease in RBF, as also suggested earlier (27, 42). It is known that the magnitude of GFR depends on the filtration forces that depend on the balance between pre- and postglomerular vascular resistances (42). In conditions in which an equipotent balance is maintained, GFR may remain the same or change in an opposite direction to the changes in RBF. Such a situation is noted during administration of many agents such as ANG II (a vasoconstrictor) or acetylcholine (a vasodilator) (42). In tempol- treated animals, an increase in NO bioavailability was further enhanced during TNF-alpha administration, resulting in an increase in RBF but GFR remained decreased, indicating a preferentially greater reduction in efferent vascular resistance in such a condition.
###end p 41
###begin p 42
###xml 430 431 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 433 434 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 445 446 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 448 449 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 453 454 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 570 572 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 643 644 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 646 647 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 665 666 645 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 668 669 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 673 674 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 856 857 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1106 1107 1078 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1109 1110 1081 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1128 1129 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1131 1132 1103 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1136 1137 1108 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1184 1185 1156 1157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1277 1279 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1281 1283 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1542 1543 1510 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 1545 1547 1513 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
The exact cause of the natriuretic response to TNF-alpha despite its vasoconstrictor and hypofiltration effects in the present study is not yet clear. However, it seems that this effect of TNF-alpha was due to its direct influence on tubular sodium reabsorption as fractional excretion of sodium increased during TNF-alpha infusion. It was reported in previous in vitro studies that TNF-alpha exerts direct inhibitory action on Na+-K+-ATPase, Na+-K+-2Cl- cotransporter, and renal epithelial sodium channel (ENaC) activity in the renal tubule. Kreydiyyeh and Markossian (35) showed that TNF-alpha reduces the activity and expression of renal Na+-K+-ATPase and the Na+-K+-2Cl- cotransporter in the kidney cortex and medulla. In another in vitro study, TNF-alpha was shown to inhibit ENaC activity which is mediated by ceramide and the PKC-dependent pathway (2). Thus it is conceivable that the natriuretic effect of TNF-alpha in the present study could be due to its direct inhibitory action on tubular sodium transporters. Further experiments are needed to examine this mechanism more comprehensively. As Na+-K+-ATPase and the Na+-K+-2Cl- cotransporter play an important role in the Na+ reabsorption in the proximal tubules and in the thick ascending limb of the loop of Henle (15, 24), it is possible that inhibition of these transporters by TNF-alpha increases distal delivery and generates signals from the macula densa cells to afferent arterioles to elicit vasoconstriction by activation of the tubuloglomerular feedback (TGF) mechanism (6, 42). Such activation of the TGF mechanism may have partially influenced the RBF and GFR responses to TNF-alpha administration in the present study. However, further stringent in vivo and in vitro experiments using a direct functional and molecular approach will be required to examine this possibility.
###end p 42
###begin p 43
###xml 62 64 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 248 249 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 251 253 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 351 353 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 420 422 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 453 455 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 592 594 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 631 633 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 660 662 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 669 670 657 658 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 698 699 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 729 731 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 970 972 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1015 1017 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1436 1438 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1600 1602 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 964 968 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1430 1434 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1594 1598 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
TNF-alpha is produced by activated neutrophils and monocytes (51); however, it can also be generated by vascular endothelial cells and by mesangial and renal tubular epithelial cells in the kidney, particularly upon inflammation and tissue injury (3, 16, 54). More specifically, ANG II has been reported to increase TNF-alpha production in monocytes (25), in the thick ascending limb of the loop of Henle in the kidney (16), and in the mammalian heart (30). Increased production of TNF-alpha has been reported in many forms of experimental hypertension such as ANG II-dependent hypertension (23), Dahl salt-sensitive hypertension (21), DOCA-salt hypertension (13), and l-NAME-induced hypertension (4). Furthermore, Guzic et al. (23) showed that blockade of TNF-alpha normalized the blood pressure in ANG II-induced hypertension. Recently, it has also been shown that chronic ANG II administration also failed to cause a hypertensive response in TNF-alpha knockout mice (48) as well as in T lymphocyte-deleted mice (23). Collectively, all these studies suggest that TNF-alpha plays a key role in the pathogenesis of hypertension and cardiovascular disease, and targeting this proinflammatory cytokine may be a valuable strategy for lowering the incidence of hypertension and subsequent cardiovascular complications. Indeed, recently we have reported that chronic infusion of ANG II did not cause hypertension in TNF-alpha knockout mice (48). However, when a chronic replacement therapy was made with recombinant TNF-alpha, ANG II caused a similar hypertensive response, as observed in wild-type mice (48). Further investigation determining the chronic effects of TNF-alpha on renal hemodynamics and excretory function and involvement of different isoforms of NOS and NADPH oxidase in these responses would provide a better insight into the physiological and pathophysiological roles of TNF-alpha in the kidney.
###end p 43
###begin p 44
###xml 309 310 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 310 311 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 396 397 388 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 397 398 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
In conclusion, present data demonstrate that TNF-alpha exerts a vasoconstrictor action but causes diuresis and natriuresis in the kidney. While a direct inhibitory action of TNF-alpha on epithelial sodium transport may cause natriuresis, our findings in the present study suggest that both an enhancement in O2- production, and thus a reduction in NO bioavailability due to its interaction with O2-, mediate the renal vasoconstrictor action of TNF-alpha.
###end p 44
###begin title 45
GRANTS
###end title 45
###begin p 46
This study was supported by National Heart, Lung, and Blood Institute Grant HL-66432.
###end p 46
###begin p 47
We gratefully acknowledge the technical support provided by Alexander Castillo.
###end p 47
###begin title 48
REFERENCES
###end title 48
###begin p 49
###xml 51 53 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 57 59 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 96 97 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 123 124 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 164 165 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 177 178 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 189 190 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 170 174 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Percent responses to TNF-alpha treatment (0.33 ng.g-1.min-1) on renal vascular resistance (RVR; A), renal blood flow (RBF; B), and glomerular filtration rate (GFR; C) in mice. *P < 0.05, **P < 0.01 vs. baseline value.
###end p 49
###begin p 50
###xml 51 53 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 57 59 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 79 80 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 115 117 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 120 121 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 158 160 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 162 163 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 175 176 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 187 188 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 217 218 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 168 172 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 248 252 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Percent responses to TNF-alpha treatment (0.33 ng.g-1.min-1) on urine flow (V; A), urinary sodium excretion rate (UNaV; B), fractional excretion of sodium (FENa; C) in mice. *P < 0.05, **P < 0.01 vs. baseline value. $P < 0.05 vs. values in control mice.
###end p 50
###begin p 51
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 286 287 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 298 299 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 279 283 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Percent responses to incremental doses (0.1, 0.3, 0.5 ng.g-1.min-1) of TNF-alpha administration on mean arterial pressure (MAP), renal vascular resistance (RVR), renal blood flow (RBF), glomerular filtration rate (GFR), urine flow (V) and urinary sodium excretion rate (UNaV) in mice. *P < 0.05, **P < 0.01 vs. baseline value.
###end p 51
###begin p 52
###xml 80 82 72 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 86 88 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 187 188 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 223 224 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 93 97 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 149 153 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 180 184 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 216 220 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Renal mRNA expression of TNF-alpha in response to TNF-alpha treatment (0.33 ng.g-1.min-1) in mice. Values are means +/- SE. Control, vehicle-treated mice. Etan, etanercept-treated mice. *P < 0.05 vs. vehicle-treated mice. #P < 0.05 vs. control value.
###end p 52
###begin p 53
###xml 111 115 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Absolute responses to TNF-alpha administration (0.33 ng/g/min) on renal hemodynamics and excretory function in mice
###end p 53
###begin p 54
###xml 25 26 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 45 46 43 44 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 59 60 57 58 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 188 190 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 225 226 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">K</sub>
###xml 265 267 263 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Na</sub>
###xml 302 305 300 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Iso</sub>
Values are means +/- SE; n = no. of animals. l-NAME, nitro-l-arginine methyl ester; RBF, renal blood flow; RVR, renal vascular resistance; GFR, glomerular filtration rate; V, urine flow; UNaV, urinary sodium excretion rate; UKV, urinary potassium excretion rate; FENa, fractional excretion of sodium; UIsoV, urinary 8-isoprostane excretion rate.
###end p 54
###begin p 55
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05,
###end p 55
###begin p 56
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01 vs. corresponding basal value.
###end p 56
###begin p 57
###xml 151 155 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Absolute responses to different doses of TNF-alpha administration on mean arterial pressure, heart rate, renal hemodynamics, and excretory function in mice
###end p 57
###begin p 58
Values are means +/- SE. MAP, mean arterial pressure; HR, heart rate.
###end p 58
###begin p 59
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05,
###end p 59
###begin p 60
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01 vs. corresponding basal value.
###end p 60

